Market Place
Sourcing Support
GSK, Sanofi, CSL nab BARDA funding for bird flu shots
05 Oct 2024 //
FIERCE PHARMA
CSL Seqirus picks up its 5th bird-flu-related BARDA award
26 Sep 2024 //
FIERCE PHARMA
CSL Seqirus Announces Fifth BARDA Award For Avian Flu
25 Sep 2024 //
PR NEWSWIRE
CSL gets $121 mln to increase stockpile for bird flu vaccines
25 Sep 2024 //
REUTERS
EU antitrust regulators accept Vifor Pharma`s pledge not to disparage rival
23 Jul 2024 //
REUTERS
Finland to start bird flu vaccinations for humans, in world first
26 Jun 2024 //
REUTERS
US nears deal to fund Moderna`s bird flu vaccine trial, FT reports
29 May 2024 //
REUTERS
US, European nations consider vaccinating workers exposed to bird flu
25 May 2024 //
REUTERS
Australia`s CSL tests `dynamic pricing` of donor blood amid cost surge
06 May 2024 //
REUTERS
US FDA approves Pfizer`s gene therapy for rare bleeding disorder
27 Apr 2024 //
REUTERS
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating CSL112
11 Feb 2024 //
PR NEWSWIRE
CSL`s Garadacimab Receives FDA and EMA Filing Acceptance
14 Dec 2023 //
PR NEWSWIRE
CSL and uniQure Win 2023 Prix Galien USA Award
27 Oct 2023 //
PR NEWSWIRE
CSL tanks as Novo Nordisk`s kidney trial success stokes competition concerns
12 Oct 2023 //
REUTERS
CSL Seqirus Announces Third U.S. Gov. Award in Relation to Influenza A(H5N8)
28 Aug 2023 //
PR NEWSWIRE
Record plasma collections spark a revenue boost for CSL
16 Aug 2023 //
FIERCE PHARMA
Australian biotech CSL sees upbeat 2024 after profit, dividend beat
15 Aug 2023 //
REUTERS
CSL Begins Shipping Portfolio of Influenza Vaccines for the 2023/24 U.S. Season
17 Jul 2023 //
PR NEWSWIRE
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Ph 3 DUPLEX
02 May 2023 //
PR NEWSWIRE
CSL Opens New, State-of-the-Art Vaccine R&D Facility in Waltham, Massachusetts
27 Mar 2023 //
PR NEWSWIRE
CSL links drug to rare disease benefits, plans global filings
27 Feb 2023 //
FIERCE BIOTECH
CSL`s HOPE-B Data Published in the New England Journal of Medicine
23 Feb 2023 //
PR NEWSWIRE
First Gene Therapy for Hemophilia B, CSL`s HEMGENIX, Approved by EC
21 Feb 2023 //
PR NEWSWIRE
Every drug approved in 2022: A year of fewer new products, gene-therapy firsts
03 Jan 2023 //
ENDPTS
EU Regulator Backs Gene Therapy To Treat Rare Bleeding Disorder
17 Dec 2022 //
PRESS RELEASE
CSL Appoints Paul McKenzie As CEO
13 Dec 2022 //
NASDAQ
CSL Announces Closing of Collaboration and Licensing Agreement with Arcturus
12 Dec 2022 //
PRNEWSWIRE
CSL`s HEMGENIX Demonstrates Durable Protection Factor IX Activity Levels
10 Dec 2022 //
PRNEWSWIRE
CSL invests $900 M in new Australian plasma fractionation facility
09 Dec 2022 //
BIOSPECTRUMASIA
Pharvaris, pushing through trial pause, sees shares surge with new study results
09 Dec 2022 //
BIOPHARMADIVE
CSL’s Hemgenix Gene Therapy Does Not Need A REMS
05 Dec 2022 //
PINK SHEET
FDA approves first gene therapy for hemophilia B
23 Nov 2022 //
BIOPHARMADIVE
CSL Seqirus and Arcturus Ink $4.3 Billion mRNA Vaccine Deal
03 Nov 2022 //
BIOSPACE
CSL Enters Licensing Agreement with Arcturus for Next Generation mRNA Vaccine
01 Nov 2022 //
PRNEWSWIRE
CSL Seqirus to trial avian vaccine candidate in $30M BARDA deal
10 Oct 2022 //
FIERCEPHARMA
CSL Announces Positive Preclinical Data for sa-mRNA Influenza Vaccine Candidates
05 Oct 2022 //
PRNEWSWIRE
CSL’s haemophilia B gene therapy could unlock market share
19 Sep 2022 //
SMH
CSL takes the wraps off R&D center as it eyes vaccines, cell and gene therapies
15 Sep 2022 //
ENPTS
CSL presents new research and development center in Marburg, Germany
13 Sep 2022 //
PRNEWSWIRE
Orphan Drug Designation granted for etranacogene dezaparvovec
09 Sep 2022 //
CSLBEHRING
EMA accepts review of CSL Vifor & Travere`s cMAA for sparsentan
22 Aug 2022 //
BUSINESSWIRE
CSL CEO determined to grow plasma collection after full-year sales dip
17 Aug 2022 //
ENDPTS
CSL Announces Positive Top-Line PIII Results for Garadacimab in HAE
17 Aug 2022 //
PRNEWSWIRE
Australia biotech giant CSL reports profit dip, flags cost spiral
17 Aug 2022 //
REUTERS
CSL launches new unified global brand identity
12 Aug 2022 //
PRESS RELEASE
CSL clears regulatory hurdles to settle $16.4b buyout of Vifor
02 Aug 2022 //
THEWEST
CDC Advisory Committee Recommends FLUAD QUADRIVALENT as Influenza Vaccine
22 Jun 2022 //
PRNEWSWIRE
Regulatory approvals delay CSL`s $11.7B takeover of Vifor
13 May 2022 //
AFR
CSL share price cracks under Vifor Pharma acquisition delay
11 May 2022 //
FOOL
CSL, plasma companies win reversal on Border Patrol blockade in paid collections
10 May 2022 //
ENDPTS
Publication of definitive end result for Vifor Pharma tender offer
28 Mar 2022 //
BUSINESSWIRE
Sanofi petitions FDA over `misleading` label for rival flu vaccine
05 Mar 2022 //
ENDPTS
Publication of provisional interim result for Vifor Pharma tender offer
02 Mar 2022 //
BUSINESSWIRE
Seqirus, U.S. Government Renew Multi-Year Agreement for Influenza
25 Feb 2022 //
PRNEWSWIRE
CSL says plasma business hit by Omicron, but demand robust
15 Feb 2022 //
REUTERS
CSL`s Seqirus flu vaccine campaign keeps ‘twindemic’ danger on front burner
04 Jan 2022 //
ENDPTS
CSL and Vifor Confirm Advanced Talks of Potential $8 Billion+ Acquisition
14 Dec 2021 //
BIOSPACE
Vifor Pharma shares jump 15% as takeover talks with CSL confirmed
11 Dec 2021 //
FXEMPIRE
